(Q37986145)

26 August 2017

Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee (English)

1 reference

26 August 2017

1

1 reference

26 August 2017

1 March 2012

1 reference

Basic and Clinical Pharmacology and Toxicology

26 August 2017

1 reference

26 August 2017

110

1 reference

26 August 2017

207-218

1 reference

26 August 2017

3

1 reference

Effect of oral ferrous sulphate on the half-life of doxycycline in man.

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Interactions with the absorption of tetracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Inhibition of norfloxacin absorption by dairy products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Milk and yoghurt do not impair the absorption of ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Enhancement of drug absorption by antacids. An unrecognised drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Bioavailability of four brands of phenytoin tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Oral activated charcoal and dapsone elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Comparison of activated charcoal and ipecac syrup in prevention of drug absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Do gastric contents modify antidotal efficacy of oral activated charcoal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of purgatives on antidotal efficacy of oral activated charcoal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Clinical pharmacokinetics of oral activated charcoal in acute intoxications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Morphine clearance and effects in newborn infants in relation to gestational age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Plasma concentrations of oral oxycodone are greatly increased in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Pharmacokinetics of intravenous paracetamol in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of migraine attacks on paracetamol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Prolongation of the Q-T interval caused by sotalol-Possible association with ventricular tachyarhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Unconsciousness associated with midazolam and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

A potentially hazardous interaction between erythromycin and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Dose of midazolam should be reduced during diltiazem and verapamil treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Concentrations and effects of buspirone are considerably reduced by rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Voriconazole drastically increases exposure to oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Grapefruit juice can increase the plasma concentrations of oral methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Rifampin drastically reduces plasma concentrations and effects of oral midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Concentrations and effects of zopiclone are greatly reduced by rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Rifampin reduces plasma concentrations and effects of zolpidem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Interaction of citrus juices with felodipine and nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Grapefruit juice substantially increases plasma concentrations of buspirone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Grapefruit juice enhances the exposure to oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Interaction between Doxycycline and Barbiturates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Effect of antiepileptic drugs on the elimination of various tetracycline derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

SLCO1B1 polymorphism and oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Cyclosporine markedly raises the plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

An update of recent moclobemide interaction data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00858.X

10.1111/J.1742-7843.2012.00858.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22348413